Safety concerns hang over new Alzheimer's treatment
Within hours, the world will have a better idea about prospects a new Alzheimer's treatment when Japanese drugmaker Eisai releases late-stage clinical trial results.
The big picture: News of a second patient death linked to the drug has dampened expectations and potentially created a more complicated path for the drug hitting the market.
Driving the news: Researchers will present the clinical trial results for Eisai and its partner Biogen's drug lecanemab this evening at the Clinical Trials on Alzheimer’s Disease conference in San Francisco.
Eisai shares fell by 6% on Tuesday after Science reported that a...